Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 8/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925032 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL30197578 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL30197599 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL16925343 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL31184432 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL18330203 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL30727455 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL29760900 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL22084450 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT | |
| SCHEMBL20337453 | 1.00 | USP2 (0.37) | USP2SMN1; SMN2GPR119EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3630770-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018218133-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | USP2 885/4885SMN1; SMN2 3305/4885GPR119 1087/4885 |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | PTPN5, PTPN2, PTPN1 | USP2 985/4885SMN1; SMN2 2965/4885GPR119 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.